Novo Nordisk

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. 

CEO
Maziar Mike Doustdar
CEOMaziar Mike Doustdar
Employees
76,302
Employees76,302
Headquarters
Bagsværd, Capital Region
HeadquartersBagsværd, Capital Region
Founded
1923
Founded1923
Employees
76,302
Employees76,302

NVO Key Statistics

Market cap
258.50B
Market cap258.50B
Price-Earnings ratio
17.41
Price-Earnings ratio17.41
Dividend yield
2.06%
Dividend yield2.06%
Average volume
19.81M
Average volume19.81M
High today
$59.88
High today$59.88
Low today
$58.27
Low today$58.27
Open price
$58.84
Open price$58.84
Volume
7.98M
Volume7.98M
52 Week high
$93.80
52 Week high$93.80
52 Week low
$43.08
52 Week low$43.08

NVO News

TipRanks 1h
Novo Nordisk’s AMAZE 1 Obesity Trial Signals Next Wave in Weight-Loss Pipeline

Novo Nordisk (NVO) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Study Overview: Novo Nordisk has launched AMAZE 1, a Ph...

Sherwood News 1h
Big Pharma enters 2026 with an appetite for deals

At the JPMorgan Healthcare Conference, biotechs and Big Pharma signaled they’re primed for M&A this year, after a big year for deals in 2025. Revolution Medici...

Big Pharma enters 2026 with an appetite for deals
TipRanks 1h
Novo Nordisk’s CagriSema Trial Completion: What Investors Should Watch in the Next Phase of the Diabetes and Obesity Race

Novo Nordisk (NVO) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Unlock hedge fund-level data and powerful investing tools...

Analyst ratings

53%

of 34 ratings
Buy
52.9%
Hold
35.3%
Sell
11.8%

More NVO News

The Motley Fool 4h
Is It Time to Dump Your Shares of Eli Lilly?

What happens with Eli Lilly's GLP-1 shot now that Novo Nordisk has come out with a GLP-1 pill? If you bought Eli Lilly (LLY 0.35%) shares five years ago, you a...

Is It Time to Dump Your Shares of Eli Lilly?
TipRanks 8h
Novo Nordisk Is Open to M&A to Bolster Obesity Drug Portfolio

Danish pharmaceutical giant Novo Nordisk (NVO) is open to big or small deals to bolster its obesity drug portfolio. In an interview with Bloomberg at the JPMorg...

Simply Wall St 17h
Is Novo Nordisk Pricing Reflect Its GLP‑1 Headlines And Recent Share Moves

If you are wondering whether Novo Nordisk is fairly priced or if the recent buzz has pushed it too far, this article walks through what the numbers actually say...

Is Novo Nordisk Pricing Reflect Its GLP‑1 Headlines And Recent Share Moves
The Motley Fool 1d
Eli Lilly vs Novo Nordisk: Which Company Will Dominate the Weight Loss Drug Market in 2026?

Both companies now aim to win in the oral weight loss drug market. Eli Lilly (LLY +0.26%) and Novo Nordisk (NVO 0.68%) have seen revenue climb in recent years...

Eli Lilly vs Novo Nordisk: Which Company Will Dominate the Weight Loss Drug Market in 2026?
Nasdaq 1d
Can Novo Nordisk Unseat Eli Lilly as the Weight Loss Drug Leader in 2026?

Key Points Novo Nordisk launched an oral version of its best-selling weight management medicine. It may not help catch up to Eli Lilly, whose oral anti-obesit...

Can Novo Nordisk Unseat Eli Lilly as the Weight Loss Drug Leader in 2026?
TipRanks 2d
Mixed options sentiment in Novo Nordisk with shares up 1.79%

Mixed options sentiment in Novo Nordisk (NVO), with shares up $1.05, or 1.79%, near $59.87. Options volume roughly in line with average with 89k contracts trade...

TipRanks 2d
Novo Nordisk Rethinks Pricing as Compounded GLP-1 Drugs Gain Ground

Novo Nordisk (NVO) CEO Mike Doustdar said that as many as 1.5 million people in the U.S. may now be using compounded versions of popular GLP-1 weight-loss drugs...

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the .